Purilogics, a Donaldson Life Sciences business, announced on July 30, 2025, the availability of its first manufacturing-grade product within its Purexa™ portfolio. This new offering is the Purexa NAEX (Novel Anion Exchange) Prep membrane technology, designed to support customers’ Good Manufacturing Practice (GMP) processes.
This technology represents an advancement in biopharmaceutical membrane chromatography development, providing solutions for critical purification steps. The availability of a manufacturing-grade product signifies its readiness for use in commercial-scale bioprocessing applications.
The introduction of Purexa NAEX Prep membrane technology reinforces Donaldson's strategic focus on expanding its Life Sciences segment with innovative solutions. This product aims to enhance efficiency and reliability for biopharmaceutical manufacturers, contributing to the development and production of life-saving therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.